| Changes of T lymphocyte subgroups after chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma |
| Received:February 18, 2023 Revised:February 27, 2023 Click here to download the full text |
| Citation of this paper:JIANG Zhi-hong,JIANG Ya-ting,WANG Xiao-na,ZHANG Yu-xin,WANG Yang-yang,WEI Zheng,ZOU Shan-hua.Changes of T lymphocyte subgroups after chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma[J].Chinese Journal of Clinical Medicine,2023,30(3):480-485 |
| Hits: 845 |
| Download times: 236 |
| Author Name | Affiliation | E-mail | | JIANG Zhi-hong | Department of Hematology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, Fujian, China | | | JIANG Ya-ting | Department of Hematology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, Fujian, China | | | WANG Xiao-na | Department of Hematology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, Fujian, China | | | ZHANG Yu-xin | Department of Hematology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, Fujian, China | | | WANG Yang-yang | Department of Hematology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, Fujian, China | | | WEI Zheng | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | wei.zheng@zs-hospital.sh.cn | | ZOU Shan-hua | Department of Hematology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, Fujian, China
Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | zou.shanhua@zs-hospital.sh.cn |
|
Abstract:Objective To investigate the change of cellular immunity and its prognostic significance in patients with diffuse large B-cell lymphoma. Methods The clinical data of 28 patients with newly diagnosed diffuse large B-cell lymphoma in the Department of Hematology, Xiamen Branch, Zhongshan Hospital, Fudan University from February 2018 to December 2020 were retrospectively analyzed. T lymphocyte subsets in peripheral blood were detected by flow cytometry at different time after chemotherapy. Results The absolute number of CD4+T lymphocytes and the CD4+/CD8+ ratio in peripheral blood of the patients decreased after chemotherapy. The absolute numbers of CD4+T lymphocytes were significantly lower after the fourth and sixth cycle chemotherapy than before chemotherapy (P<0.05), and reached the lowest value ([0.245±0.086]×109/L) after the fourth cycle chemotherapy. The CD4+/CD8+ ratios were significantly lower after the fourth and sixth cycle chemotherapy, at 3 months and 6 months after the end of chemotherapy than before chemotherapy (P<0.05). The absolute number of CD4+T lymphocyte and the CD4+/CD8+ ratio after sixth cycle chemotherapy in the complete response group were higher than those in the incomplete response group (P<0.05). The absolute number of CD4+T lymphocyte after the sixth cycle chemotherapy in the recurrent group was lower than that in the non-recurrent group
(P=0.030). Conclusions The cellular immunity of patients with diffuse large B cell lymphoma is impaired after chemotherapy. The main manifestation is that the CD4+T lymphocyte count decreases first and then increases within 6 months after treatment and the severity of the CD4+T lymphocyte decrease in the early stage after chemotherapy is related to prognosis of the patients. |
| keywords:diffuse large B-cell lymphoma T lymphocyte subgroups CD4+T lymphocyte CD4+/CD8+ratio |
| HTML View Full Text View/Add Comment Download reader |
|
|
|